Clinical trial
A Phase 1, Open-Label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M18 Given as Monotherapy in Subjects With Advanced Renal Cell Carcinoma
NCT00816686 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M18 Given as Monotherapy in Subjects With Advanced Renal Cell Carcinoma
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 31, 2008
- Completion date
- April 30, 2010
- Enrollment
- 7 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.